Qutero Indications/Uses

Treatment of schizophrenia: The antipsychotic efficacy of quetiapine was established in short-term (6 weeks) in adults and adolescents (13-17 years) schizophrenic inpatients.
The effectiveness of quetiapine in long-term use, that is, for more than 6 weeks, has not been systematically evaluated. Therefore, the physician who elects to use quetiapine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.
Treatment of acute manic episodes associated with bipolar I disorder, as either monotherapy or adjunct to lithium or divalproex: The efficacy of quetiapine in acute bipolar mania was established in 12 weeks in adults and 3 weeks in pediatric patients (10-17 years).
Treatment of depressive episodes associated with bipolar disorder: The efficacy of quetiapine was established in 8 weeks in bipolar I or bipolar II patients.
Maintenance treatment of bipolar I disorder as adjunct therapy to lithium or divalproex: The efficacy of quetiapine as adjunct maintenance therapy to lithium or divalproex was established patients with Bipolar I Disorder. The physician who elects to use quetiapine for extended periods in bipolar disorder should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.
Prevention of recurrence in patients with bipolar disorder, in patients whose manic or depressive episode has responded to quetiapine treatment.
Special Considerations in Treating Pediatric: Schizophrenia and Bipolar I Disorder: Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.